🇺🇸 FDA
Patent

US 12186369

Gene therapy strategy to restore electrical and cardiac function, and cardiac structure, in arrhythmogenic right ventricular cardiomyopathy

granted A61KA61K35/761A61K38/177

Quick answer

US patent 12186369 (Gene therapy strategy to restore electrical and cardiac function, and cardiac structure, in arrhythmogenic right ventricular cardiomyopathy) held by The Regents of the University of California expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of California
Grant date
Tue Jan 07 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
12
CPC classes
A61K, A61K35/761, A61K38/177, A61K48/00, A61K48/005